New HIV vaccine and antibody cocktail aims to free patients from daily meds
NCT ID NCT04983030
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a two-part vaccine (Ad26.Mos4.HIV and MVA-BN-HIV) combined with three broadly neutralizing antibodies (PGT121, PGDM1400, VRC07-523LS) in 28 adults with HIV who were already on suppressive antiretroviral therapy (ART). The goal was to see if this combination could safely allow participants to stop ART and keep the virus under control. The trial focused on safety, immune response, and whether the virus stayed suppressed during a temporary treatment pause.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HIV vaccine (Ad26.Mos4.HIV and MVA-BN-HIV) plus broadly neutralizing antibodies (PGT121, PGDM1400, VRC07-523LS)
What this could lead to
If successful, this approach could help people with HIV control the virus without needing daily antiretroviral therapy, potentially leading to long-term remission.
What could go wrong
This is an early-phase trial with only 28 participants, so results may not apply broadly. The treatment may not safely control the virus, and side effects like injection-site reactions or blood-clotting issues are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Orlando Immunology Center
Orlando, Florida, 32803, United States
-
UCLA CARE (Center for AIDs Research and Education)
Los Angeles, California, 90035, United States
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of Washington Positive Research
Seattle, Washington, 98104, United States
-
Washington University Clinical Trials Unit
St Louis, Missouri, 63110, United States